TY - JOUR T1 - Pre-clinical Research of Human Amnion-derived Mesenchymal Stem Cells and its First Clinical Treatment for a Severe Uremic Calciphylaxis Patient JF - medRxiv DO - 10.1101/2021.09.23.21261751 SP - 2021.09.23.21261751 AU - Lianju Qin AU - Jing Zhang AU - Yujie Xiao AU - Kang Liu AU - Yugui Cui AU - Fangyan Xu AU - Wenkai Ren AU - Yanggang Yuan AU - Chunyan Jiang AU - Song Ning AU - Ming Zeng AU - Guang Yang AU - Hanyang Qian AU - Anning Bian AU - Fan Li AU - Xiaoxue Ye AU - Shaowen Tang AU - Juncheng Dai AU - Jing Guo AU - Qiang Wang AU - Bin Sun AU - Yifei Ge AU - Chun Ouyang AU - Xueqiang Xu AU - Jing Wang AU - Yaoyu Huang AU - Hongqing Cui AU - Jing Zhou AU - Meilian Wang AU - Zhonglan Su AU - Yan Lu AU - Di Wu AU - Zhihong Zhang AU - Jingping Shi AU - Wei Liu AU - Li Dong AU - Yinbing Pan AU - Baiqiao Zhao AU - Ying Cui AU - Xueyan Gao AU - Zhanhui Gao AU - Xiang Ma AU - Aiqin Chen AU - Jie Wang AU - Meng Cao AU - Qian Cui AU - Li Chen AU - Feng Chen AU - Youjia Yu AU - Qiang Ji AU - Zhiwei Zhang AU - Mufeng Gu AU - Xiaojun Zhuang AU - Xiaolin Lv AU - Hui Wang AU - Yanyan Pan AU - Ling Wang AU - Xianrong Xu AU - Jing Zhao AU - Xiuqin Wang AU - Cuiping Liu AU - Ningxia Liang AU - Changying Xing AU - Jiayin Liu AU - Ningning Wang Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/09/24/2021.09.23.21261751.abstract N2 - Calciphylaxis is a rare disease characterized histologically by microvessel calcification and microthrombosis, with high mortality and no proven therapy. We reported a severe uremic calciphylaxis patient with progressive skin ischemia, large areas of painful malodorous ulcers and mummified legs. Because of her rapid progression and refractory to conventional therapy, human amnion-derived mesenchymal stem cells (hAMSCs) treatment was approved. Establishment and release inspection of hAMSCs, efficacy and safety assessment including cytokines secretory ability, immunocompetence, tumorigenicity and genetics analysis in vitro were introduced. We further performed acute and long-term hAMSC toxity evaluations in C57BL/6 mice/rats, abnormal immune response tests in C57BL/6 mice and tumorigenic tests in the neonatal NU nude mice. After pre-clinical research, she was treated by hAMSCs with intravenous and local intramuscular injection and external supernatants application to her ulcers. When followed up to 15 months, her blood-based markers of bone and mineral metabolism were improved, with regeneration of skin soft tissue and a more favorable profile of peripheral blood mononuclear cells. Skin biopsy after 1 month treatment showed vascular regeneration with mature non-calcified vessels within dermis and 20 months later re-epithelialization restored the integrity of damaged site. No infusion or local treatment related adverse events occurred. To the best of our knowledge, this is the first evidence for the clinical use of hAMSCs. These findings suggest hAMSCs warrant further investigation as a potential regenerative treatment for uremic calciphylaxis with effects of inhibiting vascular calcification, stimulating angiogenesis and myogenesis, anti-inflammatory and immune modulation, multi-differentiation, re-epithelialization and restorage of integrity.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04592640Funding StatementThis work was funded by the National Natural Science Foundation of China (81270408, 81570666, 81730041), International Society of Nephrology (ISN) Clinical Research Program (18-01-0247), Construction Program of Jiangsu Provincial Clinical Research Center Support System (BL2014084), Jiangsu Province Key Medical Personnel Project (ZDRCA2016002), CKD Anemia Research Foundation from China International Medical Foundation(Z-2017-24-2037), Outstanding Young and Middle-aged Talents Support Program of the First Affiliated Hospital of Nanjing Medical University(Jiangsu Province Hospital), the National Key Research and Development Program of China (2017YFC1001303), the Program of Jiangsu Province Clinical Medical Center (YXZXB2016001, BL2012009).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Because of the rapid progression of the calciphylaxis which was refractory to conventional therapy, hAMSC treatment was approved by the ethics committee of our hospital (2018-QT-001). The patient provided written informed consent in accordance with the Declaration of Helsinki. Human amniotic membranes were donated by healthy pregnant women under 35 years-of age who were undergoing C-sections for full term pregnancies and who provided written informed consent, which were approved by our hospital ethics committee (2012-SR-128).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the data will be publicly released upon publication. ER -